Esperion Therapeutics (ESPR) Accumulated Depreciation & Amortization (2018 - 2024)
Historic Accumulated Depreciation & Amortization for Esperion Therapeutics (ESPR) over the last 7 years, with Q4 2024 value amounting to $2.1 million.
- Esperion Therapeutics' Accumulated Depreciation & Amortization rose 308.15% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year increase of 308.15%. This contributed to the annual value of $2.1 million for FY2024, which is 308.15% up from last year.
- As of Q4 2024, Esperion Therapeutics' Accumulated Depreciation & Amortization stood at $2.1 million, which was up 308.15% from $2.0 million recorded in Q4 2023.
- Esperion Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $2.6 million for Q4 2022, and its period low was $1.6 million during Q4 2020.
- In the last 5 years, Esperion Therapeutics' Accumulated Depreciation & Amortization had a median value of $2.1 million in 2021 and averaged $2.1 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 5237.63% in 2020, then plummeted by 2112.9% in 2023.
- Over the past 5 years, Esperion Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $1.6 million in 2020, then surged by 30.55% to $2.1 million in 2021, then increased by 24.38% to $2.6 million in 2022, then fell by 21.13% to $2.0 million in 2023, then increased by 3.08% to $2.1 million in 2024.
- Its Accumulated Depreciation & Amortization was $2.1 million in Q4 2024, compared to $2.0 million in Q4 2023 and $2.6 million in Q4 2022.